Introduction
The most recent Neurocritical Care Society guideline for status epilepticus (SE) management in children and adults defined SE as "5 minutes or more of (i) continuous clinical and/or electrographic seizure activity or (ii) recurrent seizure activity without recovery (returning to baseline) between seizures" [1••] . Refractory status epilepticus (RSE) is defined as clinical or electrographic seizures, which persist after an adequate dose of an initial benzodiazepine and a second appropriate anti-seizure medication. In contrast to some earlier SE definitions, the current guideline definitions (1) shorten the seizure duration required for SE diagnosis and thereby prompt more rapid initial management, (2) eliminate any seizure duration requirement from the RSE definition and thereby prompt rapid progression through management steps, and (3) indicate that clinical and electrographic-only seizures should be equally targeted for management and thereby encourage increased use of electroencephalographic (EEG) monitoring to identify and manage electrographic-only seizures which may persist after clinically-evident seizures terminate.
Overall management approach
Initial SE management should involve resuscitation and an evaluation to identify any acute symptomatic SE etiologies [1••, 2] . The Neurocritical Care Society guideline provides a critical care treatment outline. These steps include noninvasive airway protection and gas exchange with head positioning (0-2 minutes), intubation if airway or gas exchange is compromised or intracranial pressure is elevated (0-10 minutes), vital signs assessment (0-2 minutes), vasopressor support if needed (5-15 minutes), neurologic examination (0-5 minutes), and placement of peripheral intravenous access for administration of emergent antiseizure medication therapy and fluid resuscitation (0-5 minutes). Initial etiologic testing should include bedside finger stick blood glucose (0-2 minutes), and lab testing including blood glucose, complete blood count, basic metabolic panel, calcium, magnesium, and antiseizure medication levels (5 minutes). Depending on the clinical scenario, other diagnostic testing may be required such as neuroimaging or lumbar puncture (0-60 minutes), other laboratory testing (including liver function tests, coagulation studies, arterial blood gas, toxicology screen, and inborn errors of metabolism screening), and continuous EEG monitoring if the patient is not waking up after clinical seizures cease (15-60 minutes) [1••] .
Evaluating for precipitating etiologies is critical because 15 %-20 % of children presenting with convulsive SE will have acute symptomatic etiologies identified [3] [4] [5] [Class IV]. The American Academy of Neurology practice parameter addressing the diagnostic assessment of a child with convulsive SE summarized data regarding testing. Among children who underwent testing, various abnormalities were identified including low anticonvulsant levels (32 %), neuroimaging abnormalities (8 %), electrolytes (6 %), inborn errors of metabolism (4.2 %), ingestion (3.6 %), central nervous system infections (2.8 %), and positive blood cultures (2.5 %) [2] . A prospective observational study of 144 children presenting with convulsive SE reported that combined computed tomography (CT) and magnetic resonance imaging (MRI) provided a diagnosis in 30 % of children. Among 44 children who underwent head CT and MRI, 14 had a normal head CT but an abnormal MRI, leading to the conclusion that MRI had a superior yield and should be considered whenever available if head CT is nondiagnostic [3] [Class IV]. Some centers use rapid sequence MRI as a first line imaging modality if it is available and feasible for a given child to avoid exposure to CT radiation.
Medication management aims to terminate clinical and electrographic seizures. The guideline states that "definitive control of SE should be established within 60 minutes of onset" [1••] . In contrast to some earlier SE management algorithms, which considered medications as first, second, and third line agents, the new guideline uses the terms emergent, urgent, and refractory to help convey a sense of time urgency. Medications used for SE management are discussed in more detail below.
The guideline emphasizes the need for rapid management because of increasing animal model evidence that prolonged seizures cause neuronal injury and are associated with an increased risk for subsequent epilepsy and unfavorable behavioral and cognitive outcomes. Further, there is increasing clinical evidence that persisting seizures become more self-sustaining and pharmacoresistant. An observational study of 157 children with seizures lasting longer than 5 minutes reported that treatment delays exceeding 30 minutes were associated with delays in achieving seizure control [6] [Class IV]. An observational study of 27 children documented that first and second line medications were effective in terminating SE in 86 % of subjects when seizure duration was less than 20 minutes at presentation and only 15 % of subjects when seizure duration exceeded 30 minutes [7] [Class IV]. A retrospective study of 358 children found that midazolam efficacy was significantly lower when treatment was initiated more than 3 hours after seizure onset, and there was a trend toward reduced efficacy even at 1 hour [8] [Class IV]. These findings may be explained by data indicating that with continuing seizures, inhibitory gamma-aminobutyric acid receptors are internalized, resulting decreased inhibitory control [9, 10] .
There are two main indications for performing urgent EEG monitoring. First, if psychogenic SE is suspected then diagnosis using EEG monitoring may avoid continued exposure to anticonvulsant medications and pharmacologic coma induction with potential adverse effects [11, 12] [Class IV]. Second, there is increasing data that after convulsive SE terminates, some patients have persisting electrographic-only (nonconvulsive) seizures. These may occur when convulsive seizures terminate with anticonvulsant administration but electrographic seizures persist (electroclinical uncoupling or dissociation), or when paralytics are required as part of the management strategy and clinically-evident convulsions are thereby masked. The recent SE management guideline states that in order to identify electrographic seizures, "continuous electroencephalographic monitoring should be initiated within one hour of status epilepticus onset if ongoing seizures are suspected." The guideline recommends 48 hours of EEG monitoring to identify possible nonconvulsive seizures in children with recent SE without return to baseline mental status in 10 minutes, in patients with known acute symptomatic brain injury including traumatic brain injury, stroke, coma after cardiac arrest, or in patients with altered mental status [ . These studies all included children who underwent continuous EEG monitoring, and studies have not prospectively evaluated consecutive patients after convulsive SE termination to determine the true incidence or risk factors for persisting electrographic seizures. In addition, further study is needed to determine whether aggressive identification and management of electrographic seizures improves outcome.
While entirely evidence-based pathways are not available and variation occurs in SE management [21•] , there is increasing data indicating the importance of a management plan to expedite therapeutic decisions and avoid treatment delays. A recent consensus document stressed the importance of written protocol, which provide a clear structured time frame [22] . An example SE management pathway is provided in Fig. 1 . One study evaluating the management of children with convulsive SE reported that laboratory parameters were often not checked and long delays often occurred in obtaining glucose results when it was checked [23] [Class IV]. Anticonvulsant management in children with convulsive SE is often delayed or involves dosing outside of recommended guidelines. A retrospective multicenter study reported that even once in the emergency department, the median time to administer a second-line anticonvulsant to a seizing child was 24 minutes [24] [Class IV]. Benzodiazepine dosing has been reported to be outside usual dosing guidelines in 23 % of children with convulsive SE [23] [Class IV]. Excess benzodiazepine dosing, which often occurs when prehospital doses have been administered, contributes to respiratory insufficiency and need for intensive care unit admission [23, 25, 26] [Class IV]. Having a management pathway in place to guide management may help reduce these problems.
Benzodiazepines
Benzodiazepines are the emergent medications of choice, with specific benzodiazepines determined by the available route of administration; lorazepam for intravenous administration, midazolam for intramuscular or intranasal administration, and diazepam for rectal administration [1••] . Repeat dosing may be provided in 5-10 minutes if seizures persist. However, care should be taken to assess whether any pre-hospital benzodiazepines were administered in which case progressing to an urgent medication may be indicated. Lorazepam may be administered intravenously at 0.1 mg/kg with a repeat dose in 5 minutes, up to a maximum dose of 4 mg. Diazepam may be administered intravenously at 0.15 mg/kg with a repeat dose in 5 minutes, up to a maximum dose of 10 mg. If no intravenous access is available, midazolam may be administered intramuscularly (5 mg for 13-40 kg body weight or 10 mg for 940 kg body weight) or intranasally (0.2 mg/kg) or buccally (0.5 mg/kg). Midazolam is not approved by the Federal Drug Administration for intranasal or buccal use.
Immediate Management:
Non-invasive airway protection and gas exchange with head positioning. Intubation if needed. Monitoring O2 saturation, blood pressure heart rate, temperature. The two most common intravenous benzodiazepine options are intravenous lorazepam and diazepam. In a prospective trial, 78 children with SE were randomized to receive either intravenous lorazepam (0.1 mg/kg) or intravenous diazepam (0.2 mg/kg) plus phenytoin (18 mg/kg), and there was no difference in terms of median time to seizure termination [27] . Metaanalyses have indicated that intravenous lorazepam is at least as effective as intravenous diazepam and is associated with fewer adverse events in the treatment of acute tonic-clonic convulsions [28] [Class IV] and that midazolam administered by any route was superior to diazepam administered by any route [29] [Class IV].
Adverse effects for all these benzodiazepines include sedation, respiratory depression, and hypotension. The recent SE management guideline considers lorazepam and midazolam to be emergent treatments (Class I, Level A evidence) and diazepam to be an emergent treatment (Class IIa, Level A evidence) [ 
Since benzodiazepines are relatively short acting, unless the SE etiology has been identified and definitively corrected, all children should also receive an "urgent" medication (see below) in addition to a benzodiazepine
Phenytoin and fosphenytoin
Overview Phenytoin stabilizes the inactive form of the neuronal voltage-gated sodium channels and thereby limits repetitive firing of action potentials. Phenytoin and fosphenytoin are available in oral and intravenous formulations, respectively, and fosphenytoin can also be administered intramuscularly. Fosphenytoin is a water soluble pro-drug that is rapidly and entirely converted to phenytoin. Adverse effects Bradyarrhythmias hypotension, local tissue necrosis (including purple glove syndrome). There is a black box warning that rapid infusion increases the risk of cardiovascular adverse effects. Fosphenytoin has a lower risk of cardiovascular adverse effects and does not cause tissue necrosis if it extravasates.
Interactions Strong hepatic P450 enzyme inducer and highly protein bound.
Phenobarbital
Overview Phenobarbital is a long-acting barbiturate that enhances gammaaminobutyric acid (GABA)-mediated inhibition. Phenobarbital is available in oral and intravenous formulations.
Role and standard dosage The recent SE management guideline considers phenobarbital to be an emergent treatment option (Class IIB, Level A evidence), an urgent control treatment option (Class IIB, Level C evidence), and a refractory treatment option (Class IIB, Level C evidence) with dosing of 20 mg/kg followed by another Adverse effects Sedation, respiratory depression including need for ventilation, and hypotension. Cardiovascular and respiratory monitoring is generally required.
Contraindications Phenobarbital can worsen porphyria.
Interactions Strong hepatic enzyme inducer.
Valproic acid
Overview Valproic acid is a broad spectrum anticonvulsant that modulates sodium and calcium channels, as well as inhibitory GABAergic neurotransmission. Valproic acid is available in oral and intravenous formulations. Contraindications Active hepatitis, pancreatitis, or known or suspected mitochondrial disease.
Adverse effects Black box warnings include hepatotoxicity (highest risk in children less than two years of age, those receiving anticonvulsant polytherapy, and children with mitochondrial disorders), pancreatitis, and teratogenicity. Other adverse effects include pancytopenia, thrombocytopenia, platelet dysfunction, hypersensitivity reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis), and encephalopathy (with or without elevated ammonia).
Interactions Hepatic enzyme inhibitor and competes with other protein bound drugs.
Levetiracetam
Overview Levetiracetam is a broad spectrum anticonvulsant and the exact anticonvulsant mechanism remains unknown. Levetiracetam is not metabolized by the liver, has low protein binding, and is excreted renally. Levetiracetam is available in oral and intravenous formulations. Adverse effects Metabolic acidosis, increased intraocular pressure, oligohydrosis resulting in hyperthermia, and nephrolithiasis.
Interactions Hepatic metabolism is low when administered without enzyme inducing medications but may increase with co-administration of enzyme inducing medications such as phenytoin or phenobarbital leading to a shorter halflife.
Midazolam
Overview Midazolam is an injectable benzodiazepine that is fast acting, rapidly penetrates the blood brain barrier, and has a short duration of action. It modulates GABA receptors, which suppress neuronal excitability. 
Pentobarbital
Overview Pentobarbital is an intravenous anesthetic barbiturate that depresses neuronal excitability by enhancing GABA activity. Adverse effects Respiratory depression, hypotension, cardiac depression, paralytic ileus, infection, and suppression of brainstem reflexes.
Role and standard dosage
Contraindications Can exacerbate porphyria.
Main drug interactions Hepatic enzyme inducer.

Ketamine
Overview Ketamine is a noncompetitive N-methyl D-aspartate (NMDA)-type glutamate receptor antagonist that may be effective in later stages of RSE since it acts independently of GABA-related mechanisms that underlie benzodiazepine and barbiturate function. In addition, ketamine may be neuroprotective by reducing NMDA receptor mediated excitotoxic injury.
Role and standard dosage The recent SE management guideline considers ketamine as an emerging therapy [1••] . Only case reports and series are available reporting 0.5-2 mg/ kg intravenous loading doses followed by continuous infusions. The largest case series described nine children RSE refractory to midazolam, and also refractory to pentobarbital in five children. Ketamine was administered at a median of 6 days of RSE at a median dose of 40 mcg/kg/min, which achieved RSE control in 66 % of children. Responders received ketamine for 3-17 days and generally achieved a burst-suppression EEG pattern. No major adverse effects were reported [47] [Class IV].
Adverse effects Some studies have reported increased intracranial pressure with ketamine administration for lumbar puncture sedation [48] [Class IV]. In contrast, a literature review did not identify evidence of ketamine-induced elevations in intracranial pressure, instead ketamine administration was associated with improved cerebral perfusion [49] [Class IV]. Ketamine's sympathomimetic properties may produce hypertension and tachycardia.
Interactions Hepatic enzyme inducer and inhibitor.
Propofol
Overview Propofol is an intravenous alkyl-phenol general anesthetic thought to modulate GABA receptors that is rapidly acting, easily titrated and has a short half-life with little accumulation.
Role and standard dosage The recent SE management guideline considers propofol to be used as a refractory treatment option [Class IIB, Level B evidence] with an initial 1-2 mg/kg loading dose and initial 20 mcg/kg/min infusion titrated up by about 5-10 mcg/kg/min as needed, with caution advised with dosing above 65 mcg/kg/min in children [1••] . Few data are available. A retrospective study of 33 children with RSE indicated that propofol was more effective than thiopental in terminating seizures (64 % vs 55 %) with a mean propofol treatment duration of 57 hours. Complications including rhabdomyolysis and hypertriglyceridemia prompted discontinuation in 18 % of patients, although these lab values normalized after propofol was discontinued and no deaths were attributable to propofol [50] [Class IV].
Adverse effects Respiratory depression and hypotension. Propofol has been associated with propofol infusion syndrome (cardiac failure, rhabdomyolysis, metabolic acidosis, renal failure, and sometimes death) with risk factors including high-doses, prolonged use (although may occur in 1-2 days), supportive treatments with catecholamines and corticosteroids, and possibly with low body mass index. This complication limits the use of propofol in children [51] [Class IV].
Other therapies The diagnosis of pyridoxine-related seizures is made when administration of intravenous pyridoxine (vitamin B6) (often 100 mg given for one to five doses) terminates seizures, sometimes for several months after administration. Some children who do not respond to pyridoxine may respond to oral pyridoxal phosphate [62] [Class IV]. Because multiple medications are often being adjusted at the same time, it may be unclear whether a benefit is due to pyridoxine, time, or other co-administered medications. In the past, pyridoxine would be withdrawn to determine whether seizures recurred and if so, pyridoxine-dependent seizures were diagnosed [63] . This trial-and-error approach may now be avoided by evaluating for elevated urinary alphaaminoadipic semialdehyde or mutations in the ALDH7A1 gene [64] .
Ketogenic diet The ketogenic diet is a high fat, low carbohydrate diet that requires a precise nutrition regimen and can be administered via modified parenteral nutrition solutions or intravenously. While most patients have been treated with oral versions of the diet, intravenous ketogenic diet use has also been reported [65] [Class IV]. The ketogenic diet is considered the treatment of choice for GLUT-1 transporter deficiency and pyruvate dehydrogenase deficiency. The ketogenic diet is contraindicated in patients with porphyria, pyruvate carboxylase deficiency, disorders of fatty acid oxidation and metabolism, and some other metabolic disorders. Screening labs include serum acylcarnitine profile, amino acids, lactate, ammonia, complete blood count, electrolytes, liver function tests, and urine organic acids [66, 67] [Class IV]. Implementation is complex and multiple adverse effects may occur, necessitating an experienced team [68] . Adverse effects include hypoglycemia, metabolic acidosis, fatigue, hypertriglyceridemia, gastroesophageal reflux, emesis, con- Vagus nerve stimulation Vagus nerve stimulation has been reported effective in several case reports, but efficacy is generally over a prolonged period.
Hypothermia When used as a neuroprotective strategy for multiple types of brain injury, therapeutic hypothermia may reduce many destructive processes because of excitotoxicity, neuroinflammation, apoptosis, free radical production, seizures, and blood-brain barrier disruption. Only case reports and small case series have described the use of therapeutic hypothermia for status epilepticus, which suggest that 1-5 days of hypothermia to 32°C-36°C may terminate seizures often, seizures do not recur upon rewarming and some patients go on to have a favorable outcome. A series of five children with RSE managed with hypothermia (32°C-35°C) for 1-5 days reported RSE termination in all patients, although two of the five had seizures (but not SE) recur after warming. Three of the five were able to return home [71] [Class IV]. A report of two children aged 4 and 10 years with febrile infection-related epilepsy syndrome treated with hypothermia (33°C) within 12 hours of admission had SE termination without recurrence, and both had a Glasgow Outcome Score of 4 (moderate disability) at follow-up [72] [Class IV].
Complications include transient asymptomatic metabolic changes (hypokalemia, hypernatremia, hyperglycemia, lactic acidosis), asymptomatic coagulopathy, and hemodynamic instability.
Electroconvulsive therapy RSE is considered an indication for electroconvulsive therapy by the American Psychiatric Association Task Force Report [73] . Experimental evidence suggests that electroconvulsive therapy may augment endogenous GABA and reduce neuronal metabolic activity, thereby producing a refractory period that can terminate SE. Only case reports and small series are available. A case series of seven adults and four children with RSE reported that electroconvulsive therapy led to improvement in 80 % (often temporarily) and 27 % had full functional recovery [74] [Class IV]. Electroconvulsive therapy may also induce seizures and nonconvulsive SE [75, 76] [Class IV], so EEG monitoring after electroconvulsive therapy is generally indicated. Preexisting cardiovascular conditions are a relative contraindication to electroconvulsive therapy. 
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